Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension

Hepatology

Volumn 43, Issue 3, 2006, Pages 485-491

  Hernández Guerra, Manuel ^a   García Pagán, Juan Carlos ^a   Turnes, Juan ^a   Bellot, Pablo ^a   Deulofeu, Ramón ^a   Abraldes, Juan G ^a   Bosch, Jaime ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ASCORBIC ACID; NITRIC OXIDE; SUPEROXIDE;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; LIVER BLOOD FLOW; LIVER CIRRHOSIS; MALE; MEAL; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPAIN; VASODILATATION;

AGED; ANTIOXIDANTS; ASCORBIC ACID; DOUBLE-BLIND METHOD; ENDOTHELIUM; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PORTAL; LIVER CIRCULATION; LIVER CIRRHOSIS; MALE; MALONDIALDEHYDE; MIDDLE AGED; NITRIC OXIDE; OXIDATIVE STRESS; POSTPRANDIAL PERIOD; SPLANCHNIC CIRCULATION; SUPEROXIDES;

EID: 33645240442     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21080     Document Type: Article

References (50)

1. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000;32(1 Suppl):141-156.
2. Hernandez-Guerra M, Garcia-Pagan JC, Bosch J. Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension. J Clin Gastroenterol 2005;39(4 Suppl 2):S131-S137.
3. Kroeger RJ, Groszmann RJ. Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agents in a portal hypertensive model. HEPATOLOGY 1985;5:97-101.
4. Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985;1:325-337.
5. Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. HEPATOLOGY 1998;28:926-931.
6. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998;114:344-351.
7. Shah V, Toruner M, Haddad F, Cadelina G, Papapetropoulos A, Choo K, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the Rat. Gastroenterology 1999;117:1222-1228.
8. Bellis L, Berzigotti A, Abraldes JG, Moitinho E, Garcia-Pagan JC, Bosch J, et al. Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. HEPATOLOGY 2003;37:378-384.
9. Zafra C, Abraldes JG, Turnes J, Berzigotti A, Fernandez M, Garca-Pagan JC, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004;126:749-755.
10. Van de Casteele M., Omasta A, Janssens S, Roskams T, Desmet V, Nevens F, et al. In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats. Gut 2002;51:440-445.
11. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998;114:344-351.
12. Wever RM, van DT, van Rijn HJ, de GF, Rabelink TJ. Tetrahydrobiopterin regulates Superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem Biophys Res Commun 1997;237:340-344.
13. Van de Casteele M, Van Pelt JF, Nevens F, Fevery J, Reichen J. Low NO bioavailability in CC14 cirrhotic rat livers might result from low NO synthesis combined with decreased superoxide dismutase activity allowing superoxide-mediated NO breakdown: a comparison of two portal hypertensive rat models with healthy controls. Comp Hepatol 2003;2:2.
14. Valgimigli M, Valgimigli L, Trere D, Gaiani S, Pedulli GF, Gramantieri L, et al. Oxidative stress EPR measurement in human liver by radical-probe technique: correlation with etiology, histology and cell proliferation. Free Radic Res 2002;36:939-948.
15. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001;35:297-306.
16. Loguercio C, Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med 2003;34:1-10.
17. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998;97:2222-2229.
18. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996;97:22-28.
19. Ting HH, Timimi FK, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation 1997;95:2617-2622.
20. Solzbach U, Hornig B, Jeserich M, Just H. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation 1997;96:1513-1519.
21. Hamabe A, Takase B, Uehata A, Kurita A, Ohsuzu F, Tamai S. Impaired endothelium-dependent vasodilation in the brachial artery in variant angina pectoris and the effect of intravenous administration of vitamin C. Am J Cardiol 2001;87:1154-1159.
22. Richartz BM, Werner GS, Ferrari M, Figulla HR. Reversibility of coronary endothelial vasomotor dysfunction in idiopathic dilated cardiomyopathy: acute effects of vitamin C. Am J Cardiol 2001;88:1001-1005.
23. Jackson TS, Xu A, Vita JA, Keaney JF Jr. Ascorbate prevents the interaction of superoxide and nitric oxide only at very high physiological concentrations. Circ Res 1998;83:916-922.
24. Sherman DL, Keaney JF Jr., Biegelsen ES, Duffy SJ, Coffman JD, Vita JA. Pharmacological concentrations of ascorbic acid are required for the beneficial effect on endothelial vasomotor function in hypertension. Hypertension 2000;35:936-941.
25. Navasa M, Chesta J, Bosch J, Rodes J. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis: effects on splanchnic and systemic hemodynamics and liver function. Gastroenterology 1989;96:1110-1118.
26. Navasa M, Bosch J, Mastai R, Bruix J, Rodes J. Measurement of hepatic blood-flow, hepatic extraction and intrinsic clearance of indocyanine green in patients with cirrhosis-Comparison of a noninvasive pharmacokinetic method with measurements using hepatic vein catheterization. Eur J Gastroenterol Hepatol 1991:305-312.
27. McCormick PA, Dick R, Graffeo M, Wagstaff D, Madden A, McIntyre N, et al. The effect of non-protein liquid meals on the hepatic venous pressure gradient in patients with cirrhosis. J Hepatol 1990;11:221-225.
28. O'Brien S, Keogan M, Patchett S, McCormick PA, Afdhal N, Hegarty JE. Postprandial changes in portal haemodynamics in patients with cirrhosis. Gut 1992;33:364-367.
29. Albillos A, Rossi I, Iborra J, Lledo JL, Calleja JL, Barrios C, et al. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J Hepatol 1994;21:88-94.
30. Mittal MK, Gupta TK, Lee FY, Sieber CC, Groszmann RJ. Nitric oxide modulates hepatic vascular tone in normal rat liver. Am J Physiol 1994;267:G416-G422.
31. Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000;118:1149-1156.
32. Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. HEPATOLOGY 1996;24:233-240.
33. Titos E, Claria J, Bataller R, Bosch-Marce M, Gines P, Jimenez W, et al. Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology 2000;119:794-805.
34. Graupera M, Garcia-Pagan JC, Titos E, Claria J, Massaguer A, Bosch J, et al. 5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. Gastroenterology 2002;122:387-393.
35. Graupera M, Garcia-Pagan JC, Abraldes JG, Peralta C, Bragulat M, Corominola H, et al. Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. HEPATOLOGY 2003;37:172-181.
36. Garcia-Pagan JC, Bosch J. The resistance of the cirrhotic liver: a new target for the treatment of portal hypertension. 1985. J Hepatol 2004;40:887-890.
37. Shah V, Chen AF, Cao S, Hendrickson H, Weiler D, Smith L, et al. Gene transfer of recombinant endothelial nitric oxide synthase to liver in vivo and in vitro. Am J Physiol Gastrointest Liver Physiol 2000;279:G1023-G1030.
38. Yu Q, Shao R, Qian HS, George SE, Rockey DC. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest 2000;105:741-748.
39. Fiorucci S, Antonelli E, Morelli O, Mencarelli A, Casini A, Mello T, et al. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci U S A 2001;98:8897-8902.
40. Loureiro-Silva MR, Cadelina GW, Iwakiri Y, Groszmann RJ. A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. J Hepatol 2003;39:940-946.
41. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454-456.
42. Hamilton CA, Miller WH, Al-Benna S, Brosnan MJ, Drummond RD, McBride MW, et al. Strategies to reduce oxidative stress in cardiovascular disease. Clin Sci (Lond) 2004;106:219-234.
43. Yadav D, Hertan HI, Schweitzer P, Norkus EP, Pitchumoni CS. Serum and liver micronutrient antioxidants and serum oxidative stress in patients with chronic hepatitis C. Am J Gastroenterol 2002;97:2634-2639.
44. Paradis V, Kollinger M, Fabre M, Holstege A, Poynard T, Bedossa P. In situ detection of lipid peroxidation by-products in chronic liver diseases. HEPATOLOGY 1997;26:135-142.
45. Van de Casteele M, Zaman Z, Zeegers M, Servaes R, Fevery J, Nevens F. Blood antioxidant levels in patients with alcoholic liver disease correlate with the degree of liver impairment and are not specific to alcoholic liver injury itself. Aliment Pharmacol Ther 2002;16:985-992.
46. Bianchi G, Bugianesi E, Ronchi M, Fabbri A, Zoli M, Marchesini G. Glutathione kinetics in normal man and in patients with liver cirrhosis. J Hepatol 1997;26:606-613.
47. Jain SK, Pemberton PW, Smith A, McMahon RF, Burrows PC, Aboutwerat A, et al. Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. J Hepatol 2002;36:805-811.
48. Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-Felmayer G, Werner ER. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 2001;276:40-47.
49. d'Uscio LV, Milstien S, Richardson D, Smith L, Katusic ZS. Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ Res 2003;92:88-95.
50. Lauer T, Kleinbongard P, Keim M. Indexes of NO bioavailability in human blood. News Physiol Sci 2002;17:251-5:251-255.